TD Cowen analyst Tyler Van Buren has maintained their bullish stance on CGON stock, giving a Buy rating on March 28.
Tyler Van Buren has given his Buy rating due to a combination of factors surrounding CG Oncology, Inc.’s promising developments in their treatment for bladder cancer. The company’s lead product, cretostimogene (“creto”), has shown significant potential in treating high-risk non-muscle invasive bladder cancer (NMIBC) that is unresponsive to BCG therapy. Recent data updates from the BOND-003 trial have demonstrated creto’s superior efficacy, with an improved complete response rate and a median duration of response that exceeds existing FDA-approved therapies.
Furthermore, CG Oncology is preparing to submit a Biologics License Application (BLA) for creto in the second half of the year, which could be a major catalyst for the company. The ongoing clinical trials and upcoming data presentations are expected to further validate creto’s best-in-class profile. The anticipation of mature data and the potential for widespread adoption of creto in the medical community contribute to the positive outlook and support the Buy rating.
In another report released on March 28, LifeSci Capital also maintained a Buy rating on the stock with a $82.00 price target.